Want to see TSE:APLI full AI Analyst Report?
APLI Stock Chart & Stats
C$0.01
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.01
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)37.67K
Market Cap
C$1.99M
Enterprise ValueC$15.17
Total Cash (Recent Filing)C$138.68K
Total Debt (Recent Filing)C$13.33M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding132,366,120
10 Day Avg. Volume52,130
30 Day Avg. Volume37,669
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.11
Price to Sales (P/S)7.60
P/FCF Ratio-1.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Infectious-disease FocusA focused infectious-disease strategy targets clinically important conditions where effective therapies may have meaningful value. Concentration on unmet medical needs can support differentiated development opportunities and improve the potential strategic relevance of successful candidates over the next several quarters.
High Gross MarginThe approximately 97% gross margin indicates that reported revenue has strong direct economics before operating expenses. If revenue becomes more consistent and scales through successful development or commercialization, this profile could provide operating leverage, although current losses remain substantial.
Reported Revenue GrowthThe reported 249% revenue-growth rate shows that the company has increased its very small revenue base materially. Continued growth would demonstrate progress toward a more productive business model, broaden potential funding options, and improve the foundation for future operating leverage.
Bears Say
Negative Equity And LeverageNegative equity combined with debt that is large relative to the asset base materially weakens financial flexibility. This structure can increase refinancing and dilution pressure, constrain investment in clinical programs, and make the company more vulnerable if funding conditions remain challenging.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is not currently self-funding its activities. Continued cash burn creates recurring financing needs and can divert management attention toward capital raising, while increasing the risk that future funding dilutes existing shareholders.
Deep Operating LossesVery small revenue alongside deeply negative operating and net margins shows that the company has not yet reached a sustainable earnings base. Without stronger and more consistent revenue, fixed development and corporate costs are likely to keep consuming capital over the medium term.
Appili Therapeutics Inc Class A News
APLI FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is C$1.99M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Nov 12, 2026 which is in 52 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Aug 14, 2026. The company reported -C$0.013 earnings per share for the quarter.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 132,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -C$0.013 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in TSE:APLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).